|
NCI Clinical Trials and Translational Research Advisory Committee (CTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NCI
|
The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process. The Committee will provide advice on matters related to the conduct, oversight, and implementation of clinical trials and translational research across the Institute.
|
|
NCI National Cancer Informatics Program (NCIP) Nanotechnology Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NCI, NHLBI, NIBIB, NIEHS
|
The National Cancer Institute National Cancer Informatics Program (NCIP) Nanotechnology Working Group (NCIP Nano WG) was established in 2008 for researchers with a specific interest in informatics and computational approaches to nanotechnology, with a particular emphasis on nanomedicine. The goal of this Working Group is to demonstrate the scientific potential of federating nanotechnology databases through pilot projects aimed at integrated semantic search and retrieval of nanomedicine and nanotoxicology datasets that are applicable across nanoscience. The NCIP Nano WG comprises over 20 active participants from academia, government, and industry with diverse interests.
|
|
NCI/CCR-FDA Clinical Investigator Program
|
Research Initiative
|
FDA
|
NCI
|
Multilateral Benefit in a Joint Program to Recruit Combined Food and Drug Administration (FDA) and the National
Cancer Institute''s (NCI) Center for Cancer Research (CCR) Clinical Investigators: the FDA gains an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field; NCI gains a clinical investigator and leader who understands regulatory considerations in drug development; and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind
|
|
NCI/FDA Memorandum of Understanding for Drug Related Information
|
Resource Development
|
FDA
|
NCI
|
The National Cancer Institute (NCI) Enterprise Vocabulary Services is working with the US Food and Drug Administration (FDA) to develop and support controlled terminology in several areas. More than 24,000+ FDA terms and codes are stored in the NCI Thesaurus.
|
|
NCI/FDA Memorandum of Understanding for Proteomics
|
Research Initiative
|
FDA
|
NCI
|
This Memorandum of Understanding (MOU), signed in 2007 and renewed in 2012, establishes an official relationship in clinical proteomic regulatory science between the National Cancer Institute''s (NCI) Office of Cancer Clinical Proteomics Research and the Food and Drug Administration (FDA). Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development.
|
|
Networking and Information Technology Research and Development (NITRD)
|
Research Initiative
|
AHRQ
|
NIGMS
|
The Networking and Information Technology Research and Development (NITRD) Program provides a framework in which many Federal agencies come together to coordinate their networking and information technology (IT) research and development (R&D) efforts.
|
|
New Molecular Methods for Evaluation of Antibody Responses Following RSV Vaccination and Infection
|
Other
|
FDA
|
NIAID
|
The goal of the project is to identify the key protective epitopes in F and G membrane proteins and to develop new tools to measure virus neutralization and antibody affinity.
|
|
Newborn Screening Coding and Terminology Guide
|
Resource Development
|
CDC, HRSA, OS
|
NLM, NHGRI, NHLBI, NICHD
|
This ongoing collaboration develops, supplements, and publicizes a free online resource with guidance to help promote the efficient electronic exchange of standardized newborn screening data. Related efforts include studying the screening process for diseases including severe combined immunodeficiency (SCID), lysosomal storage disorders (LSDs), and critical congenital heart disease (CCHD), and developing standard codes for ordering and reporting the results of newborn screening for SCID, CCHD, and other conditions added to the Uniform Recommended Screening Panel by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children.
|
|
Newborn Screening Federal Partners Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA
|
NICHD, NHLBI, NLM
|
The National Institutes of Health, Health Resources and Services Administration, Centers for Disease Control and Prevention (CDC), the American College of Medical Genetics and the Genetic Alliance meet monthly, in person or online, to discuss and coordinate current activities and initiatives in newborn screening. Topics include the activities of the Newborn Screening Translational Research Network Coordinating Center, the Clearinghouse of Newborn Screening Information, Sickle Cell Screening Programs, the CDC Newborn Screening Quality Assurance Program, and the Regional Newborn Screening Collaboratives.
|
|
NEWSteps Steering Committee
|
Committee, Work group, Advisory group, or Task Force
|
HRSA
|
NICHD
|
This steering committee supports the mission of NEWSteps, which is to achieve the highest quality for newborn screening systems by providing relevant, accurate tools and resources and to facilitate collaboration between state programs and other newborn screening partners.
|